{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T16:15:38Z","timestamp":1791389738497,"version":"4.3.3"},"reference-count":37,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"7","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JCO Global Oncology"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:sec><jats:title>PURPOSE<\/jats:title><jats:p> With intense HIV epidemics, southern African countries have a high burden of classic Hodgkin lymphoma (CHL) and non-Hodgkin lymphoma (NHL). However, suboptimal access to pathology resources limits subtype classification. We sought to assess the diagnostic accuracy of specimens classified as lymphoma and to determine association between discordant pathologic diagnosis and overall survival. <\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS<\/jats:title><jats:p> Seventy patients with CHL or NHL and treated at three Botswana hospitals from 2010 to 2016 were analyzed. Local pathologic assessment relied primarily on morphology. All cases underwent secondary US hematopathology review, which is considered gold standard. <\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p> The median follow-up was 58 months. The overall reclassification rate was 20 of 70 cases (29%). All 20 CHL cases were correctly classified in Botswana, and mixed cellularity was the most common subtype, diagnosed in 11 (55%) cases. Of 47 confirmed NHL cases, diffuse large B-cell lymphoma was the final US diagnosis in 28 cases (60%), another aggressive B-cell NHL in nine (19%), an indolent B-cell NHL in six (13%), and T-cell NHL in four (9%). Common types of diagnostic discordance included NHL subtype reclassification (11 of 20, 55%) and CHL reclassified as NHL (7 of 20, 35%). Concordant versus discordant diagnosis after secondary review was associated with improved 5-year overall survival (60.1% v 26.3%, P = .0066). Discordant diagnosis was independently associated with increased risk of death (adjusted hazard ratio 2.733; 95% CI, 1.102 to 6.775; P = .0300) even after stratifying results by CHL versus NHL. <\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSION<\/jats:title><jats:p> In this single prospective cohort, discordant pathologic diagnosis was associated with a nearly three-fold increased risk of death. Limited access to relatively basic diagnostic techniques impairs treatment decisions and leads to poor patient outcomes in low-resource countries. <\/jats:p><\/jats:sec>","DOI":"10.1200\/go.21.00209","type":"journal-article","created":{"date-parts":[[2021,12,3]],"date-time":"2021-12-03T20:59:42Z","timestamp":1638565182000},"page":"1620-1632","update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":5,"title":["Accuracy of Pathologic Diagnosis in Patients With Lymphoma and Survival: A Prospective Analysis From Botswana"],"prefix":"10.1200","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2696-1339","authenticated-orcid":false,"given":"Fallon E.","family":"Chipidza","sequence":"first","affiliation":[{"name":"Harvard Radiation Oncology Program, Harvard Medical School, Boston, MA"},{"name":"Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2632-169X","authenticated-orcid":false,"given":"Mukendi K. A.","family":"Kayembe","sequence":"additional","affiliation":[{"name":"University of Botswana, Gaborone, Botswana"},{"name":"Ministry of Health, Gaborone, Botswana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isaac","family":"Nkele","sequence":"additional","affiliation":[{"name":"Botswana Harvard AIDS Institute, Gaborone, Botswana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0996-0350","authenticated-orcid":false,"given":"Jason A.","family":"Efstathiou","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce A.","family":"Chabner","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital Cancer Center, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8467-9257","authenticated-orcid":false,"given":"Jeremy","family":"Abramson","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital Cancer Center, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8487-9731","authenticated-orcid":false,"given":"Scott L.","family":"Dryden-Peterson","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, Brigham and Women's Hospital, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6307-4854","authenticated-orcid":false,"given":"Aliyah R.","family":"Sohani","sequence":"additional","affiliation":[{"name":"Department of Pathology, Massachusetts General Hospital, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"b1","volume-title":"Country Factsheets: Botswana 2018"},{"key":"b2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(16)00037-0"},{"key":"b3","doi-asserted-by":"crossref","first-page":"e0135602","DOI":"10.1371\/journal.pone.0135602","volume":"10","author":"Dryden-Peterson S","year":"2015","journal-title":"PLoS One"},{"key":"b4","doi-asserted-by":"publisher","DOI":"10.1002\/hon.977"},{"key":"b5","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13885"},{"key":"b6","doi-asserted-by":"publisher","DOI":"10.7196\/SAMJ.2018.v108i7.12844"},{"key":"b7","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2017-0643"},{"key":"b8","first-page":"1","volume":"4","author":"Milligan MG","year":"2018","journal-title":"JCO Glob Oncol"},{"key":"b9","volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"Swerdlow SH","year":"2017"},{"key":"b10","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2011.08772.x"},{"key":"b11","doi-asserted-by":"publisher","DOI":"10.5858\/2009-0443-EP.1"},{"key":"b12","first-page":"339","volume":"4","author":"Orem J","year":"2012","journal-title":"Clin Epidemiol"},{"key":"b13","doi-asserted-by":"publisher","DOI":"10.1186\/1756-0500-5-149"},{"key":"b14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa055759"},{"key":"b15","doi-asserted-by":"publisher","DOI":"10.4103\/0971-5851.133721"},{"key":"b16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa055351"},{"key":"b17","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0b013e3181cd3aeb"},{"key":"b18","doi-asserted-by":"publisher","DOI":"10.1186\/s12981-017-0139-x"},{"key":"b19","doi-asserted-by":"publisher","DOI":"10.7196\/SAMJ.6093"},{"key":"b20","doi-asserted-by":"publisher","DOI":"10.1200\/JGO.2015.000299"},{"key":"b21","first-page":"1","volume":"4","author":"Vogt SL","year":"2018","journal-title":"JCO Glob Oncol"},{"key":"b22","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0150445"},{"key":"b23","doi-asserted-by":"publisher","DOI":"10.1097\/00126334-200104010-00015"},{"key":"b24","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(12)70598-3"},{"key":"b25","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000000862"},{"key":"b26","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcmd.2004.10.003"},{"key":"b27","doi-asserted-by":"publisher","DOI":"10.4102\/ajlm.v9i1.979"},{"key":"b28","doi-asserted-by":"publisher","DOI":"10.1093\/ajcp\/aqaa218"},{"key":"b29","doi-asserted-by":"publisher","DOI":"10.1097\/01.PAT.0000454438.78930.54"},{"key":"b30","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s00292-019-0641-0","volume":"40","author":"V\u00f6lker H-U","year":"2019","journal-title":"Pathologe"},{"key":"b31","first-page":"1","volume":"4","author":"Muvugabigwi G","year":"2018","journal-title":"JCO Glob Oncol"},{"key":"b32","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2015.11.010"},{"key":"b33","doi-asserted-by":"publisher","DOI":"10.1016\/j.cll.2017.10.007"},{"key":"b34","doi-asserted-by":"publisher","DOI":"10.1016\/j.cll.2017.10.011"},{"key":"b35","doi-asserted-by":"publisher","DOI":"10.1093\/ajcp\/aqw118"},{"key":"b36","doi-asserted-by":"publisher","DOI":"10.1016\/j.cll.2017.10.006"},{"key":"b37","doi-asserted-by":"publisher","DOI":"10.1200\/JGO.2015.000943"}],"container-title":["JCO Global Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/GO.21.00209","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,29]],"date-time":"2022-05-29T08:14:13Z","timestamp":1653812053000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/GO.21.00209"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":37,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["10.1200\/GO.21.00209"],"URL":"https:\/\/doi.org\/10.1200\/go.21.00209","relation":{},"ISSN":["2687-8941"],"issn-type":[{"value":"2687-8941","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"2021-06-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-07-22","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-10-27","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-12-03","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}